Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Akers Biosciences and Premas Biotech have reported positive proof-of-concept data from animal studies of their PRAK-03202 vaccine candidate against Covid-19.
A four-week test in mice met its primary endpoints of safety and immune response, said the companies. The vaccine candidate was well-tolerated and safe in the animals, with an encouraging immune response.
During the preclinical study, 50 mice across ten cohorts received 5, 10 and 20μg of the vaccine candidate, found to be generally well-tolerated and safe at all doses, without any adverse events.